{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:05:23Z","timestamp":1792130723505,"version":"4.4.0"},"reference-count":95,"publisher":"Informa UK Limited","issue":"6","funder":[{"name":"funded"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2024,6,2]]},"DOI":"10.1080\/13543784.2024.2348743","type":"journal-article","created":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T08:58:30Z","timestamp":1714208310000},"page":"627-638","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Investigational farnesoid X receptor agonists for the treatment of primary biliary cholangitis"],"prefix":"10.1080","volume":"33","author":[{"given":"Prithvi Reddy","family":"Akepati","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Gochanour","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA"},{"name":"The Gastroenterology Center, Valley View Hospital, Glenwood Springs, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,5,7]]},"reference":[{"key":"e_1_3_4_3_1","first-page":"G265","article-title":"On a certain affection of the skin-vitiligoidea-\u03b1-plana \u03b2-tuberosa","volume":"7","author":"Addison T","year":"1851","unstructured":"Addison T, Gull W. On a certain affection of the skin-vitiligoidea-\u03b1-plana \u03b2-tuberosa. Guys Hosp Rept. 1851;7:G265\u2013277.","journal-title":"Guys Hosp Rept"},{"issue":"3","key":"e_1_3_4_4_1","first-page":"387","article-title":"Primary biliary cirrhosis. Chronic non-suppurative destructive cholangitis","volume":"46","author":"Rubin E","year":"1965","unstructured":"Rubin E, Schaffner F, Popper H. Primary biliary cirrhosis. Chronic non-suppurative destructive cholangitis. Am J Pathol. 1965 Mar;46(3):387\u2013407.","journal-title":"Am J Pathol"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.05.005"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1603324"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2019.05.006"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2013.01.028"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(85)90213-6"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198301063080101"},{"issue":"3","key":"e_1_3_4_11_1","first-page":"759","article-title":"A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis","volume":"22","author":"Combes B","year":"1995","unstructured":"Combes B, Carithers RL Jr, Maddrey WC, et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 1995 Sep;22:(3):759\u2013766.","journal-title":"Hepatology"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1996.v110.pm8613058"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2000.20240"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(03)00192-2"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.12.029"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.07.061"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.01.003"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00423.x"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.12.007"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(05)80214-4"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm025529g"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509840"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0226-7"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0000000000000703"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2008.03.009"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12224"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0039.1994.tb02303.x"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(05)80617-8"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-11148-6"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.181.5.1835"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810440"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/0090-1229(86)90049-8"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI4213"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI0214698"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26979"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510230108"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.216"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.01.007"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23405"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510260118"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1993.1927"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)72197-2"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1042\/bst0030825"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00424-006-0152-8"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21042"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfi061"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.25086"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0265418"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.02.020"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25691"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(95)90530-8"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.284.5418.1365"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.284.5418.1362"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(00)80348-2"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232213967"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1089\/1044549041562267"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M400102-JLR200"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI21025"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2005.09.001"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M700330-JLR200"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23708"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M011610200"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.25503"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23876"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.42.29749"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M500417-JLR200"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00170.2004"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.08.001"},{"issue":"1","key":"e_1_3_4_69_1","first-page":"767","article-title":"[Abstract]. EDP-305, a novel and selective farnesoid X receptor agonist, exhibits high potency and efficacy in vitro and in vivo","volume":"64","author":"Li Y","year":"2016","unstructured":"Li Y, Chau MD, Wang G, et al. [Abstract]. EDP-305, a novel and selective farnesoid X receptor agonist, exhibits high potency and efficacy in vitro and in vivo. Hepatology. 2016;64(Supplement S1):767.","journal-title":"Hepatology"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.11648\/j.ijg.20190301.12"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm0002127"},{"key":"e_1_3_4_72_1","volume-title":"The International Liver Congress\u2122, EASL - European Association for the Study of the Liver (EASL)","author":"Liles JT","year":"2016","unstructured":"Liles JT, Karnik S, Hambruch E, et al. PS066: FXR agonism by GS-9674 decreases steatosis and fibrosis in a murine model of NASH. The International Liver Congress\u2122, EASL - European Association for the Study of the Liver (EASL); Barcelona, Spain. Apr 2016."},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b00907"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-023-00444-4"},{"key":"e_1_3_4_75_1","unstructured":"GSRS. Content current as of 12\/16\/23 GSRS website nih. [cited 2023 Jan 2]. Available from: https:\/\/gsrs.ncats.nih.gov\/ginas\/app\/beta\/substances\/US5Q3KD5RD"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm500889f"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.08.029"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.12.005"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.08.054"},{"key":"#cr-split#-e_1_3_4_80_1.1","unstructured":"A phase 4 double-blind randomized placebo-controlled multicenter study evaluating the effect of obeticholic acid on clinical outcomes in patients with primary biliary cholangitis. Sponsored by intercept pharmaceuticals. ClinicalTrials.gov identifier: NCT02308111. [Published 2023 Mar 9"},{"key":"#cr-split#-e_1_3_4_80_1.2","unstructured":"cited 2024 Jan 11]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02308111"},{"key":"e_1_3_4_81_1","unstructured":"FDA drug safety podcast content current as of 01\/11\/2022 Food and drug administration website US government [cited 2023 Dec 1]. Available from: https:\/\/www.fda.gov\/drugs\/fda-drug-safety-podcasts\/due-risk-serious-liver-injury-fda-restricts-use-obeticholic-acid-ocaliva-primary-biliary-cholangitis"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI64551"},{"issue":"1","key":"e_1_3_4_83_1","first-page":"323A","article-title":"[Abstract]. The novel farnesoid X receptor (FXR) agonist, EDP-305, reduces fibrosis progression in bile duct ligated rats","volume":"64","author":"Farrar CT","year":"2016","unstructured":"Farrar CT, Wei L, Choi J-K, et al. [Abstract]. The novel farnesoid X receptor (FXR) agonist, EDP-305, reduces fibrosis progression in bile duct ligated rats. Hepatology. 2016;64(Supplement S1):323A.","journal-title":"Hepatology"},{"issue":"1","key":"e_1_3_4_84_1","first-page":"746A","article-title":"[Abstract]. Final data of the phase 2a INTREPID study with EDP-305, a non-bile acid farnesoid X receptor (FXR) agonist. Sponsored by Enanta Pharmaceuticals","volume":"72","author":"Kowdley KV","year":"2020","unstructured":"Kowdley KV, Bonder A, Michael A, et al. [Abstract]. Final data of the phase 2a INTREPID study with EDP-305, a non-bile acid farnesoid X receptor (FXR) agonist. Sponsored by Enanta Pharmaceuticals. Hepatology. 2020;72(Supplement S1):746A. Clinicaltrials.gov identifier: NCT03394924.","journal-title":"Hepatology"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2018.1459569"},{"issue":"1","key":"e_1_3_4_86_1","first-page":"71A","article-title":"[Abstract]. Pharmacodynamic effects of the non-steroidal farnesoid X receptor (FXR) agonist GS-9674 in high fat, high cholesterol diet fed cynomolgus monkeys","volume":"64","author":"French D","year":"2016","unstructured":"French D, Liles JT, Liu H, et al. [Abstract]. Pharmacodynamic effects of the non-steroidal farnesoid X receptor (FXR) agonist GS-9674 in high fat, high cholesterol diet fed cynomolgus monkeys. Hepatology. 2016;64(Supplement S1):71A.","journal-title":"Hepatology"},{"issue":"1","key":"e_1_3_4_87_1","first-page":"543A","article-title":"[Abstract]. Pharmacodynamic effects of the oral, non-steroidal farnesoid X receptor agonist GS-9674 in healthy volunteers","volume":"64","author":"Djedjos CS","year":"2016","unstructured":"Djedjos CS, Kirby B, Billin A, et al. [Abstract]. Pharmacodynamic effects of the oral, non-steroidal farnesoid X receptor agonist GS-9674 in healthy volunteers. Hepatology. 2016;64(Supplement S1):543A.","journal-title":"Hepatology"},{"issue":"1","key":"e_1_3_4_88_1","first-page":"31a","article-title":"[Abstract]. The nonsteroidal farnesoid X receptor (FXR) agonist cilofexor improves liver biochemistry in patients with primary biliary cholangitis (pbc): a phase 2, randomized, placebo-controlled trial","volume":"70","author":"Kowdley KV","year":"2019","unstructured":"Kowdley KV, Minuk GY, Pagadala MR, et al. [Abstract]. The nonsteroidal farnesoid X receptor (FXR) agonist cilofexor improves liver biochemistry in patients with primary biliary cholangitis (pbc): a phase 2, randomized, placebo-controlled trial. Hepatology. 2019;70(Supplement S1):31a.","journal-title":"Hepatology"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30509"},{"issue":"1","key":"e_1_3_4_90_1","first-page":"S97","article-title":"[Abstract]. A novel, highly potent, non-bile acid FXR agonist for the treatment of NASH and cholestasis","volume":"10","author":"Laffitte B","year":"2016","unstructured":"Laffitte B, Young K, Joseph S, et al. [Abstract]. A novel, highly potent, non-bile acid FXR agonist for the treatment of NASH and cholestasis. Hepatol Int. 2016;10(Supplement S1):S97.","journal-title":"Hepatol Int"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.762"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100544"},{"key":"e_1_3_4_93_1","unstructured":"Novartis clinical trial results CLJN452X2201 content current date: unavailable clinical trial results website. [cited 2023 Dec 12]. Available from: https:\/\/www.novctrd.com\/ctrdweb\/patientsummary\/patientsummaries?patientSummaryId=322"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-023-00444-4"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2023.2264850"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.2147\/HMER.S361077"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2024.2348743","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T18:09:41Z","timestamp":1727201381000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2024.2348743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,7]]},"references-count":95,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6,2]]}},"alternative-id":["10.1080\/13543784.2024.2348743"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2024.2348743","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,7]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-01-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}